- ORION indirect treatment comparison using OASIS-4 and ATTAIN-1 data found oral semaglutide 25 mg produced ~3.0–3.2 percentage-point greater mean weight loss versus orforglipron 36 mg.
- Orforglipron 36 mg showed higher odds of treatment discontinuation versus oral semaglutide 25 mg: OR 4.1 for any adverse events and OR 13.9 for GI-related adverse events (~14×).
- FDA approved orforglipron as Foundayo up to 17.2 mg tablets, equivalent to the 36 mg capsules used in ATTAIN-1 Phase 3 trials.
- OPTIC patient-preference survey (n=800) found 84% favored an oral semaglutide-like profile; results were presented at Obesity Medicine Association 2026 in San Diego.
ORION study
Population-adjusted indirect treatment comparison using OASIS‑4 (oral semaglutide 25 mg) and ATTAIN‑1 (orforglipron 36 mg) data; simulated treatment comparison for percent change in body weight and a two‑stage matching‑adjusted indirect comparison for tolerability; analyses adjusted for baseline weight, glycemic status and sex.
Key results
Oral semaglutide 25 mg showed greater mean weight loss vs orforglipron 36 mg: −3.2 percentage points (95% CI −5.9, −0.4) for the treatment‑regimen estimand and −3.0 (95% CI −5.8, −0.3) for the efficacy estimand; orforglipron had higher odds of discontinuation (OR 4.1 [1.3,13.0] for any AE; OR 13.9 [2.0,96.0] for GI‑related AEs).
Limitations and interpretation
Results adjusted for key covariates but may be affected by residual confounding and between‑trial protocol differences; tolerability findings are significant but the magnitude should be interpreted cautiously due to low AE counts; no head‑to‑head trials exist.
OPTIC patient‑preference survey
Online discrete‑choice survey of 800 US adults with overweight/obesity found 84% favored a semaglutide‑like profile over an orforglipron‑like profile and 65% said semaglutide‑style dosing (empty stomach, wait 30 minutes) would not disrupt daily life; study limited by selection bias, hypothetical profiles and timing before regulatory approval.
Regulatory and safety notes
FDA approved orforglipron as Foundayo up to 17.2 mg tablets, equivalent to the 36 mg capsules used in ATTAIN‑1; semaglutide 25 mg tablets carry a boxed warning for possible thyroid tumors/MTC/MEN2 and list common adverse reactions including nausea, diarrhea, vomiting and constipation.
